Is there a need for a national or a global apheresis registry?

Transfusion and Apheresis Science

Volumn 29, Issue 2, 2003, Pages 179-185

  Stegmayr, Bernd ^a   Korach, Jean Michel ^b   Norda, Rut ^c   Rock, Gail ^c   Fadel, Fouad ^d  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b General Hospital   (France)

^c Department of Transfusion Medicine ^*  (Canada)

^d REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse event; Apheresis; Diagnoses; Plasma exchange; Registry; Substitution

Indexed keywords

APHERESIS; ARTICLE; CANADA; CELL SEPARATION; CYTAPHERESIS; DATA ANALYSIS; EPIDEMIOLOGICAL DATA; FRANCE; HEALTH CARE ORGANIZATION; HUMAN; INTERNET; PLASMAPHERESIS; REGISTER; STEM CELL; SWEDEN; TECHNIQUE; TREATMENT INDICATION;

EID: 0042664043     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00145-9     Document Type: Article

References (42)

1. Korach J.M., Bussel H., Annane D., Gajdos P. 1991 registry of the French Society of Hemapheresis (SFH): preliminary results for the first year of the on-line computer access file. The Registry Study Group. Transfus. Sci. 14:1993;281-285.
2. Korach J.M., Bussel A., Dinet N. Development of indications and techniques of plasma exchange. Contribution of the French Registry of Hemapheresis. Group Cooperatif Francais. Ann. Med. Interne. 146:1995;13-17.
3. Korach J.M., Bussel A., Gajdos P. International forum: France. The national survey of plasma exchange and therapeutic cytapheresis in France. Transfus. Sci. 16:1995;363-370.
4. Korach J.M., Berger P., Giraud C., Le Perff-Desman C., Chillet P. Role of replacement fluids in the immediate complications of plasma exchange. French Registry Cooperative Group. Intens. Care Med. 24:1998;452-458.
5. Korach J.M., Guillevin L., Petitpas D., Berger P., Chillet P. Apheresis registry in France: indications, techniques, and complications. French Registry Study Group [In Process Citation]. Ther. Apher. 4:2000;207-210.
6. Sutton D.M., Nair R.C., Rock G. Complications of plasma exchange. Transfusion. 29:1989;124-127.
7. Rock G., Shumak K., Nair R. A study of plasma exchange in TTP. The Canadian Apheresis Study Group. Prog. Clin. Biol. Res. 337:1990;125-127.
8. Rock G., Tricklebank G. Five years of therapeutic plasma exchange in Canada. Canadian Apheresis Study Group. Prog. Clin. Biol. Res. 337:1990;523-526.
9. Rock G.A., Tricklebank G.W., Kasaboski C.A. Plasma exchange in Canada. The Canadian Apheresis Study Group. CMAJ. 142:1990;557-562.
10. Rock G.A., Herbert C.A. Therapeutic apheresis in Canada. The Canadian Apheresis Study Group. J. Clin. Apher. 7:1992;47-48.
11. Shumak K.H., Rock G.A., Nair R.C. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann. Interne Med. 122:1995;569-572.
12. Rock G., Shumak K.H., Sutton D.M., Buskard N.A., Nair R.C. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br. J. Haematol. 94:1996;383-386.
13. Leblond P.F., Rock G., Herbert C.A. The use of plasma as a replacement fluid in plasma exchange. Canadian Apheresis Group. Transfusion. 38:1998;834-838.
14. Buskard N., Rock G., Nair R. The Canadian experience using plasma exchange for immune thrombocytopenic purpura. Canadian Apheresis Group. Transfus. Sci. 19:1998;295-300.
15. Clark W.F., Rock G.A., Buskard N.et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group [see comments]. Ann. Intern. Med. 131:1999;453-462.
16. Rock G., Herbert C. The Canadian Apheresis Group and therapeutic plasma exchange. Transfus. Sci. 20:1999;145-150.
17. Norda R., Stegmayr B.G. Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study group. Transfus. Apher. Sci. 24:2001;49-55.
18. Shimizu M., Tsuda H., Sanaka T., Ide K. Present status of therapeutic apheresis in Japan: survey report (Survey Subcommittee, Scientific Committee, Japanese Society for Apheresis). Ther. Apher. 2:1998;172-181.
19. Ilhan O., Uskent N., Arslan O.et al. National survey of hemapheresis practice in Turkey 1998. Transfus. Sci. 22:2000;195-201.
20. De Silvestro G., Marson P., Vicarioto M., Donadel C. A preliminary survey of the apheresis activity in Italy: a perspective for the Italian Registry of apheresis. Int. J. Artif. Organs. 23:2000;114-118.
21. McLeod B.C., Price T.H., Owen H.et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 38:1998;938-943.
22. McLeod B.C., Sniecinski I., Ciavarella D.et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 39:1999;282-288.
23. Aringer M., Smolen J.S., Graninger W.B. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum. 41:1998;414-420.
24. Sanz-Guajardo D. Plasmapheresis in the treatment of glomerulonephritis: indications and complications. Am. J. Kidney Dis. 36:2000;LIV-LVI.
25. Schlenke P., Frohn C., Steinhardt M.M., Kirchner H., Kluter H. Clinically relevant hypokalaemia, hypocalcaemia, and loss of hemoglobin and platelets during stem cell apheresis. J. Clin. Apher. 15:2000;230-235.
26. Malchesky P.S., Skibinski C.I., Williams G.W., Nose Y. The International Apheresis Registry: results of 1983 second pilot. Artif. Organs. 11:1987;173-182.
27. Malchesky P.S., Skibinski C.I. Summary of results of 1991 ASFA apheresis survey. American Society for Apheresis. J. Clin. Apher. 8:1993;96-101.
28. Malchesky P.S., Koo A.P., Rybicki L.A. Apheresis technologies and clinical applications: the 2000 International Apheresis Registry. Ther. Apher. 5:2001;193-206.
29. Stegmayr B.G., Banga R., Berggren L., Norda R., Rydvall A., Vikerfors T. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit. Care Med. 31:2003;1630-1636.
30. Norda R., Berseus O., Stegmayr B. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus. Apher. Sci. 25:2001;33-41.
31. ®, a lower substitued hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5 Anesth. Analg. 92:2001;855-862.
32. Franz A., Braeunlich P., Foringer C., Kozek S.A. The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth. Analg. 92:2001;1402-1407.
33. Schettler V., Wieland E., Armstrong V.W., Kleinoeder T., Grunewald R.W., Muller G.A. First steps toward the establishment of a german low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management. Ther. Apher. 6:2002;381-383.
34. Stegmayr B. Is there a place for LDL-apheresis in non-homozygous patients? Int. J. Artif. Organs. 22:1999;723-725. [editorial].
35. Busund R., Koukline V., Utrobin U., Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intens. Care Med. 28:2002;1434-1439.
36. Nguyen T.C., Kiss J., Hall M.W., Carillo J.A. Randomized control trial of plasma exchange therapy for thrombocytopenia associated multiple organ failure in children. Crit. Care Med. 28S:2000;A49.
37. Szpirt W.M., Rasmussen N., Petersen J. Long term outcome and prognostic factors in randomized study of plasma exchange and cyclosporin-A in Wegener's granulomatosis. J. Am. Soc. Nephrol. 182A:1999;. [ASN. Abstract A0932].
38. Gaskin G., Jayne D.R.et al. EVS. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 13:2002;2A-3A.
39. Suckfull M., Group HLS Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet. 360:2002;1811-1817.
40. Pulido J.S., Group MIoRfAM-S Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans. Am. Ophthalmol. Soc. 100:2002;85-107.
41. Muller J., Wallukat G., Dandel M., Bieda H., Brandes K., Spiegelsberger S.et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 101:2000;385-391.
42. Schimke I., Muller J., Priem F., Kruse I., Schon B., Stein J.et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J. Am. Coll. Cardiol. 38:2001;178-183.